One US-made drug treats congenital syphilis, and the country is running short

The United States is facing a critical shortage of Bicillin L-A, the sole first-line medication recommended for treating syphilis in pregnant women to prevent congenital syphilis transmission to babies. This shortage is particularly alarming as congenital syphilis rates have been skyrocketing, highlighting the urgency for effective treatment. Pfizer's voluntary recall of Bicillin L-A last July has exacerbated the situation, underscoring the dire need for alternative solutions and increased production to address this public health crisis.